Search Results | Blood | American Society of Hematology

1-20 of 68

2 3 4

Sort by

Sort Order Select

Journal Articles

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Jacob Edmisson, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Jingyu Xiang, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, John F. DiPersio, Ravi Vij

Blood (2022) 140 (Supplement 1): 4295–4296.

DOI: https://doi.org/10.1182/blood-2022-169367

Published: 2022

Journal Articles

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Christopher Strouse, Christopher A. Yasenchak, Damian J. Green, Jeremy Sauer, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 10160–10162.

DOI: https://doi.org/10.1182/blood-2022-157347

Published: 2022

Journal Articles

The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study

Lawrence Liu, Mei Wang, Nikhil Grandhi, Mark A. Schroeder, Theodore S. Thomas, Akhil Kumar, Kristin Vargo, Feng Gao, Kristen M. Sanfilippo, Su-Hsin Chang

Blood (2022) 140 (Supplement 1): 4356–4357.

DOI: https://doi.org/10.1182/blood-2022-167305

Published: 2022

Journal Articles

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Alexa J Loncharich, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Kari Wilson, Mark A. Schroeder, Keith E Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo

Blood (2022) 140 (Supplement 1): 8550–8551.

DOI: https://doi.org/10.1182/blood-2022-166736

Published: 2022

Journal Articles

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Michael J Slade, Abir Khalid, Mark A Fiala, Mariya Liyasova, Mark A Zaydman, Zac McDonald, Julie M Fortier, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2022) 140 (Supplement 1): 4376–4377.

DOI: https://doi.org/10.1182/blood-2022-155582

Published: 2022

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

DOI: https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

DOI: https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

Meagan A. Jacoby, David A. Sallman, Bart L. Scott, Megan Haney, Fei Wan, John F. DiPersio, Ramzi Abboud, Keith E. Stockerl-Goldstein, Rami S. Komrokji, Mark A. Schroeder, Matthew J. Walter, Peter Westervelt, Geoffrey L. Uy

Blood (2021) 138 (Supplement 1): 540.

DOI: https://doi.org/10.1182/blood-2021-151137

Published: 2021

Journal Articles

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Ramzi Abboud, Feng Gao, Michael P. Rettig, Jeremy Eisele, Leah Gehrs, Nichols Wallace, Camille Abboud, Sr., Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matt Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E. Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder

Blood (2021) 138 (Supplement 1): 100.

DOI: https://doi.org/10.1182/blood-2021-144591

Published: 2021

Journal Articles

A Single Center Retrospective Analysis of Letermovir for Cytomegalovirus Prophylaxis after Allogeneic Stem Cell Transplant in Cytomegalovirus Seropositive Recipients or Donors

Lawrence Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Mark A. Schroeder

Blood (2021) 138 (Supplement 1): 2864.

DOI: https://doi.org/10.1182/blood-2021-146350

Published: 2021

Journal Articles

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

James E Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Michael H. Tomasson, Christopher A. Yasenchak, Damian J. Green, Hong Li, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2021) 138 (Supplement 1): 2740.

DOI: https://doi.org/10.1182/blood-2021-146047

Published: 2021

Journal Articles

Financial Toxicity Among Patients with Multiple Myeloma

Alice Silberstein, Mark A. Fiala, Sarah Kelley, Mark A. Schroeder, Keith E. Stockerl-Goldstein, Ravi Vij

Blood (2021) 138 (Supplement 1): 4027.

DOI: https://doi.org/10.1182/blood-2021-153653

Published: 2021

Journal Articles

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela Hobbs, Haesook T. Kim, AJ S. Bottoms, Michael T. Byrne, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Zachariah Defilipp, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen

Blood (2021) 138 (Supplement 1): 169.

DOI: https://doi.org/10.1182/blood-2021-146330

Published: 2021

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

DOI: https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Hannah Choe, MD, Nirav N. Shah, MD, Patrice Chevallier, MD PhD, Marie Thérèse Rubio, MD PhD, Mark A. Schroeder, MD, Nancy M. Hardy, MD, Patrick J. Stiff, MD, Carlos Solano, MD PhD, Ibrahim Yakoub-Agha, Jonathan A. Gutman, MD, Scott D. Rowley, MD, Maria Caterina Mico', MD, Elisabetta Terruzzi, MD, Rafael F. Duarte, MD PhD FRCP, Rodica Morariu-Zamfir, MD, Michael Arbushites, Kai Ding, PhD, Miguel-Angel Perales, MD

Blood (2020) 136 (Supplement 1): 50–51.

DOI: https://doi.org/10.1182/blood-2020-140747

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

DOI: https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Lawrence Liu, MD, Gao Feng, MD PhD MPH, Mark A. Fiala, MSW, Justin King, BS, Scott R. Goldsmith, MD, Tanya M. Wildes, MD MSCI, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS, Mark A. Schroeder, MD

Blood (2020) 136 (Supplement 1): 31–32.

DOI: https://doi.org/10.1182/blood-2020-137023

Published: 2020

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

DOI: https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

DOI: https://doi.org/10.1182/blood-2019-131135

Published: 2019

Journal Articles

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Justin King, Mark A. Fiala, BS, Scott R. Goldsmith, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Tanya M. Wildes, MD

Blood (2019) 134 (Supplement_1): 5701.

DOI: https://doi.org/10.1182/blood-2019-130689

Published: 2019

2 3 4

NARROW

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

A Single Center Retrospective Analysis of Letermovir for Cytomegalovirus Prophylaxis after Allogeneic Stem Cell Transplant in Cytomegalovirus Seropositive Recipients or Donors

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Financial Toxicity Among Patients with Multiple Myeloma

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only